Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Other Working Capital Changes (2020 - 2025)

Historic Other Working Capital Changes for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to $53000.0.

  • Vivos Therapeutics' Other Working Capital Changes rose 10809.16% to $53000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$954000.0, marking a year-over-year increase of 1231.62%. This contributed to the annual value of -$1.4 million for FY2024, which is 7235.58% down from last year.
  • Vivos Therapeutics' Other Working Capital Changes amounted to $53000.0 in Q3 2025, which was up 10809.16% from -$109000.0 recorded in Q2 2025.
  • In the past 5 years, Vivos Therapeutics' Other Working Capital Changes ranged from a high of $922000.0 in Q2 2021 and a low of -$784000.0 during Q2 2024
  • In the last 5 years, Vivos Therapeutics' Other Working Capital Changes had a median value of -$140000.0 in 2023 and averaged -$62157.9.
  • In the last 5 years, Vivos Therapeutics' Other Working Capital Changes plummeted by 58000.0% in 2023 and then skyrocketed by 46000.0% in 2024.
  • Vivos Therapeutics' Other Working Capital Changes (Quarter) stood at -$27000.0 in 2021, then soared by 459.26% to $97000.0 in 2022, then crashed by 257.73% to -$153000.0 in 2023, then tumbled by 226.14% to -$499000.0 in 2024, then skyrocketed by 110.62% to $53000.0 in 2025.
  • Its last three reported values are $53000.0 in Q3 2025, -$109000.0 for Q2 2025, and -$399000.0 during Q1 2025.